Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 170 results for asthma

  1. Indoor air quality at home (NG149)

    This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.

  2. Anaphylaxis: assessment and referral after emergency treatment (CG134)

    This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services.

  3. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

  4. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

    In development Reference number: GID-TA11429 Expected publication date:  25 September 2026

  5. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

  6. Atopic eczema in under 12s: diagnosis and management (CG57)

    This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.

  7. Food allergy (QS118)

    This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.

  8. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

  9. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

    In development Reference number: GID-TA11564 Expected publication date:  22 July 2026

  10. Diagnosing asthma in adults (aged 17 and over):- What is the clinical and cost effectiveness of using an indirect bronchial challenge test with mannitol to diagnose asthma in adults (aged 17 and over)?

    Recommendation ID NG80/2 Question Diagnosing asthma in adults (aged 17 and over):- What is the clinical and cost effectiveness of using

  11. Preventing excess winter deaths and illness associated with cold homes (QS117)

    This quality standard covers reducing the health risks (including preventable deaths) associated with cold homes. It includes identifying people at risk who are particularly vulnerable to the cold, such as young children, older people, and people with cardiovascular disease or mental health problems. It describes high-quality care in priority areas for improvement.

  12. Inhaled therapies for people with COPD and asthma- What is the clinical and cost effectiveness of inhaled therapies (bronchodilators and/or inhaled corticosteroids) in people with both stable COPD and asthma?

    NG115/3 Question Inhaled therapies for people with COPD and asthma- What is the clinical and cost effectiveness of inhaled therapies...

  13. Social care for older people with multiple long-term conditions (QS132)

    This quality standard covers the planning and delivery of social care and support for older people (aged 65 and over) with multiple long-term conditions. It includes people living in their own homes, in specialist settings or in care homes, both those who receive support with funding for their social care and those who do not. It describes high-quality care in priority areas for improvement.

  14. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

    In development Reference number: GID-TA11552 Expected publication date:  25 September 2026

  15. Smoking: smoking status of people with long-term conditions (IND156)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126